Literature DB >> 32956181

ESPGHAN 'biopsy-sparing' guidelines for celiac disease in children with low antitransglutaminase during COVID-19.

Chiara Maria Trovato1, Monica Montuori, Salvatore Cucchiara, Salvatore Oliva.   

Abstract

OBJECTIVES: Recent guidelines for celiac disease have allowed a biopsy-free approach in endomysial antibodies (EMAs) positive children with high antitransglutaminase (TGA-IgA) titer [>10 time upper limit of normal (ULN)]. Esophagogastroduodenoscopy is still necessary for diagnosis in children with lower title. Because elective pediatric endoscopy has been substantially shouted down during coronavirus disease (COVID-19) pandemic, many children remained undiagnosed - and therefore untreated - for a long time. We aimed to analyze the feasibility and accuracy of a biopsy-free approach in suspected celiac disease children with TGA-IgA values <10 ULN to facilitate the diagnostic process by avoiding endoscopy.
METHODS: In this study cohort, we retrospectively analyzed all biopsy-confirmed diagnosis of celiac disease in our center (between 2014 and 2019). The positive predictive value (PPV) of TGA-IgA titers between 5 and 10 ULN and positive EMA in diagnosing celiac disease were determined. Mucosal atrophy and resolution of symptoms after gluten-free diet (GFD) were considered to confirm initial diagnosis.
RESULTS: Of 430 celiac disease patients (F: 274; mean age 7.54 years) diagnosed by endoscopy, 84 (F: 46; mean age 8 years) with TGA-IgA between 5 and 10 ULN and positive EMA were identified. The PPV of TGA-IgA between 5 and 10 ULN and positive EMA was 0.93 (95% confidence interval 0.90-0.96). All these children had a symptom resolution and antibodies normalization after GFD.
CONCLUSION: During the COVID-19 outbreak, a temporarily reduction of the TGA-IgA threshold for biopsy-sparing approach seems feasible in EMA positive children with TGA-IgA between 5 and 10 ULN.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32956181     DOI: 10.1097/MEG.0000000000001924

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  7 in total

Review 1.  Review on pediatric coeliac disease from a clinical perspective.

Authors:  Margreet Wessels; Renata Auricchio; Jernej Dolinsek; Ester Donat; Peter Gillett; Karl Mårild; Caroline Meijer; Alina Popp; M Luisa Mearin
Journal:  Eur J Pediatr       Date:  2022-01-15       Impact factor: 3.183

Review 2.  Implications of SARS-COV-2 infection in the diagnosis and management of the pediatric gastrointestinal disease.

Authors:  Valeria Dipasquale; Stefano Passanisi; Ugo Cucinotta; Antonio Cascio; Claudio Romano
Journal:  Ital J Pediatr       Date:  2021-03-24       Impact factor: 2.638

3.  Current guidelines for the management of celiac disease: A systematic review with comparative analysis.

Authors:  Alberto Raiteri; Alessandro Granito; Alice Giamperoli; Teresa Catenaro; Giulia Negrini; Francesco Tovoli
Journal:  World J Gastroenterol       Date:  2022-01-07       Impact factor: 5.742

4.  New-onset celiac disease in children during COVID-19 pandemic.

Authors:  Murat Cakir; Burcu Guven; Fatma Issi; Esra Ozkaya
Journal:  Acta Paediatr       Date:  2021-11-11       Impact factor: 4.056

5.  Impact of COVID-19 pandemic on pediatric endoscopy: A multicenter study on behalf of the SIGENP Endoscopy Working Group.

Authors:  Sara Renzo; Luca Scarallo; Luca Maria Antoniello; Matteo Bramuzzo; Andrea Chiaro; Fabio Cisarò; Anna Chiara Iolanda Contini; Gian Luigi De Angelis; Paola De Angelis; Giovanni Di Nardo; Enrico Felici; Silvia Iuliano; Francesco Macchini; Cecilia Mantegazza; Stefano Martelossi; Salvatore Oliva; Flavia Parrinello; Francesca Rea; Antonio Pizzol; Claudio Romano; Giusy Russo; Naire Sansotta; Paolo Lionetti
Journal:  Dig Liver Dis       Date:  2022-03-09       Impact factor: 5.165

6.  The best is the enemy of the good: Time for a biopsy-sparing approach for Helicobacter pylori diagnosis and treatment in children in the COVID-19 era?

Authors:  Alice Monzani; Paolo Lionetti; Ivana Rabbone; Elena Lionetti
Journal:  Helicobacter       Date:  2021-05-28       Impact factor: 5.182

Review 7.  Twelve Months with COVID-19: What Gastroenterologists Need to Know.

Authors:  Giulia Concas; Michele Barone; Ruggiero Francavilla; Fernanda Cristofori; Vanessa Nadia Dargenio; Rossella Giorgio; Costantino Dargenio; Vassilios Fanos; Maria Antonietta Marcialis
Journal:  Dig Dis Sci       Date:  2021-07-31       Impact factor: 3.487

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.